Analysts are quick to pan Eli Lilly's puzzling first cut of positive clinical data for its Covid-19 antibody

John Carroll

Editor & Founder

Eli Lilly spotlighted a success for one of 3 doses of their closely-watched Covid-19 antibody drug Wednesday morning. But analysts quickly highlighted some obvious anomalies …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Analysts are quick to pan Eli Lilly's puzzling first cut of positive clinical data for its Covid-19 antibody

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

An­a­lysts are quick to pan Eli Lil­ly's puz­zling first cut of pos­i­tive clin­i­cal da­ta for its Covid-19 an­ti­body

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Analysts are quick to pan Eli Lilly's puzzling first cut of positive clinical data for its Covid-19 antibody